AU729488B2 - Compositions and methods for administering integrin receptor antagonists - Google Patents

Compositions and methods for administering integrin receptor antagonists Download PDF

Info

Publication number
AU729488B2
AU729488B2 AU40862/97A AU4086297A AU729488B2 AU 729488 B2 AU729488 B2 AU 729488B2 AU 40862/97 A AU40862/97 A AU 40862/97A AU 4086297 A AU4086297 A AU 4086297A AU 729488 B2 AU729488 B2 AU 729488B2
Authority
AU
Australia
Prior art keywords
inhibiting
patient
eye
receptor antagonist
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU40862/97A
Other languages
English (en)
Other versions
AU4086297A (en
Inventor
Robert J. Gould
George D. Hartman
Michael F Sugrue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9619583.9A external-priority patent/GB9619583D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU4086297A publication Critical patent/AU4086297A/en
Application granted granted Critical
Publication of AU729488B2 publication Critical patent/AU729488B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU40862/97A 1996-08-29 1997-08-25 Compositions and methods for administering integrin receptor antagonists Ceased AU729488B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2580896P 1996-08-29 1996-08-29
US60/025808 1996-08-29
GB9619583 1996-09-19
GBGB9619583.9A GB9619583D0 (en) 1996-09-19 1996-09-19 Compositions and methods for administering integrin receptor antagonists
PCT/US1997/014908 WO1998008518A1 (en) 1996-08-29 1997-08-25 Compositions and methods for administering integrin receptor antagonists

Publications (2)

Publication Number Publication Date
AU4086297A AU4086297A (en) 1998-03-19
AU729488B2 true AU729488B2 (en) 2001-02-01

Family

ID=26310068

Family Applications (1)

Application Number Title Priority Date Filing Date
AU40862/97A Ceased AU729488B2 (en) 1996-08-29 1997-08-25 Compositions and methods for administering integrin receptor antagonists

Country Status (5)

Country Link
EP (1) EP0928194A4 (ja)
JP (1) JP2001501597A (ja)
AU (1) AU729488B2 (ja)
CA (1) CA2263998A1 (ja)
WO (1) WO1998008518A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067972A1 (en) * 2001-02-28 2002-09-06 Duke University Method of inducing vitreous detachment
JP2007005582A (ja) 2005-06-24 2007-01-11 Asm Japan Kk 基板搬送装置及びそれを搭載した半導体基板製造装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
US5470849A (en) * 1990-11-01 1995-11-28 Smithkline Beecham Corp. γ-turn peptidomimetics as fibrinogen antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332384A1 (de) * 1993-09-23 1995-03-30 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten III
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229366A (en) * 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
US5470849A (en) * 1990-11-01 1995-11-28 Smithkline Beecham Corp. γ-turn peptidomimetics as fibrinogen antagonists

Also Published As

Publication number Publication date
EP0928194A1 (en) 1999-07-14
JP2001501597A (ja) 2001-02-06
EP0928194A4 (en) 2001-01-17
CA2263998A1 (en) 1998-03-05
AU4086297A (en) 1998-03-19
WO1998008518A1 (en) 1998-03-05

Similar Documents

Publication Publication Date Title
US20060183693A1 (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
US20200323844A1 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
JP2001504456A (ja) インテグリン拮抗薬
US20080226718A1 (en) Indole and Azaindole Derivatives For the Treatment of Inflammatory and Autoimmune Diseases
US6235706B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
JP2011252012A (ja) シクロペプチドおよび化学治療剤または血管新生阻害剤を含有する医薬製剤
AU723315B2 (en) Combination therapy for reducing the risks associated with cardiovascular disease
AU2006272497A1 (en) Small compounds that correct protein misfolding and uses thereof
JP6883917B2 (ja) 結晶性関節障害を処置するためのｃｘｃｒ−２阻害剤
JP2000508319A (ja) αｖβ３拮抗薬
US6251852B1 (en) Combination therapy for reducing the risks associated with cardiovascular disease
EP1420790B1 (en) Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine
WO1997035579A1 (en) A method for inhibiting clot formation
CA2727627C (en) Use of histamine h4 antagonist for the treatment of post-operative adhesions
AU740941B2 (en) Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
MXPA04001868A (es) Uso de compuestos de pirrol anillados en el tratamiento de la degeneracion del hueso sub-condrial o cartilago articular.
US5900414A (en) Methods for administering integrin receptor antagonists
AU729488B2 (en) Compositions and methods for administering integrin receptor antagonists
GB2327672A (en) 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine
US20040248816A1 (en) Treatment of migraine
CA2520930A1 (en) Use of the hydrochloride of the active ingredient base 1-[n<sp>2</sp>-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine combined with sumatriptan for the treatment of migraines
JPH11503721A (ja) ベンズアミド誘導体の新規用途
US11058707B2 (en) Methods for treating ischemic heart disease by targeting TRPV4
US20030139342A1 (en) Method of inducing vitreous detachment
WO2002020566A2 (de) NEUE MMP-2-DERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿3?

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired